SynthesisJournal of critical care2020
Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
Synthesis in Journal of critical care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04632719 (MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19), which is not on this map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer.BMC cancer · 2022Pooled it
- Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.Reviews in medical virology · 2021Pooled it
- Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.Scientific reports · 2021Trial
- Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction.Toxicologic pathology · 2024Article
- Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.Naunyn-Schmiedeberg's archives of pharmacology · 2023Observational
- Article
- Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.Journal of clinical pharmacology · 2022Article
- Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates.Molecules (Basel, Switzerland) · 2022Review
- Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination.The Science of the total environment · 2022Review
- Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro.Molecules (Basel, Switzerland) · 2022Article
- Hydroxychloroquine Adsorption in Aqueous Medium Using Clinoptilolite Zeolite.Water, air, and soil pollution · 2022Article
- Immunomodulatory therapies for COVID-19.Frontiers in medicine · 2022Review
- Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.Advances in rheumatology (London, England) · 2021Observational
- QT interval and repolarization dispersion changes during the administration of hydroxychloroquine/chloroquine with/without azithromycin in early COVID 19 pandemic: A prospective observational study from two academic hospitals in Indonesia.Journal of arrhythmia · 2021Article
- System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.Expert review of anti-infective therapy · 2021Article
- Pharmacological management of COVID-19 in type 2 diabetes.Journal of diabetes and its complications · 2021Review
- One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview.Annals of global health · 2021Review
- Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.British journal of clinical pharmacology · 2021Review
- An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease.Journal of public health research · 2021Article
- Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. MATERIALS AND
methodsMEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19.
resultsThirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low.
conclusionsPatients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.